Abstract
Culinary and medicinal mushrooms are widely used in Asian countries, both as dietary supplements and as nutraceutical foods. They have recently become popular in Europe, as well, for their nutritional and health benefits. In particular, epidemiological studies conducted in Asia suggest that mushroom intake, together with other phytotherapy substances, protects against cancer, specifically gastrointestinal (GI) and breast cancers. Most of the data come from in vitro studies and in vivo experimental animal models. Therefore, in order to translate the updated knowledge to clinical research (i.e., from bench to bedside) a systematic translational research program should be initiated. Future randomized controlled trials comparing the effects of G. frondosa and G. lucidum on conventional treatment outcomes are warranted. The purpose of this review was to describe the emerging mechanisms of action of the mushrooms' anticancer functions which makes their use in clinical practice so promising. Clinical effects of mycotherapy (specifically, the use of Ganoderma lucidum and Grifola frondosa) on long-term survival, tumor response, host immune functions, inflammation, and QoL in cancer patients were also addressed. Adverse events associated with mycotherapy were also investigated. Emerging data point to a potential role of G. lucidum for modulating the carcinogenic potential of GI microbiota, which suggests a new complementary and integrated approach to breast cancer treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 24837-24856 |
| Number of pages | 20 |
| Journal | Oncotarget |
| Volume | 9 |
| Issue number | 37 |
| DOIs | |
| Publication status | Published - May 15 2018 |
Fingerprint
Cite this
B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer : an example of complementary and integrative medicine. / Rossi, Paola; Difrancia, Raffaele; Quagliariello, Vincenzo; Savino, Elena; Tralongo, Paolo; Randazzo, Cinzia Lucia; Berretta, Massimiliano.
In: Oncotarget, Vol. 9, No. 37, 15.05.2018, p. 24837-24856.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer
T2 - an example of complementary and integrative medicine
AU - Rossi, Paola
AU - Difrancia, Raffaele
AU - Quagliariello, Vincenzo
AU - Savino, Elena
AU - Tralongo, Paolo
AU - Randazzo, Cinzia Lucia
AU - Berretta, Massimiliano
PY - 2018/5/15
Y1 - 2018/5/15
N2 - Culinary and medicinal mushrooms are widely used in Asian countries, both as dietary supplements and as nutraceutical foods. They have recently become popular in Europe, as well, for their nutritional and health benefits. In particular, epidemiological studies conducted in Asia suggest that mushroom intake, together with other phytotherapy substances, protects against cancer, specifically gastrointestinal (GI) and breast cancers. Most of the data come from in vitro studies and in vivo experimental animal models. Therefore, in order to translate the updated knowledge to clinical research (i.e., from bench to bedside) a systematic translational research program should be initiated. Future randomized controlled trials comparing the effects of G. frondosa and G. lucidum on conventional treatment outcomes are warranted. The purpose of this review was to describe the emerging mechanisms of action of the mushrooms' anticancer functions which makes their use in clinical practice so promising. Clinical effects of mycotherapy (specifically, the use of Ganoderma lucidum and Grifola frondosa) on long-term survival, tumor response, host immune functions, inflammation, and QoL in cancer patients were also addressed. Adverse events associated with mycotherapy were also investigated. Emerging data point to a potential role of G. lucidum for modulating the carcinogenic potential of GI microbiota, which suggests a new complementary and integrated approach to breast cancer treatment.
AB - Culinary and medicinal mushrooms are widely used in Asian countries, both as dietary supplements and as nutraceutical foods. They have recently become popular in Europe, as well, for their nutritional and health benefits. In particular, epidemiological studies conducted in Asia suggest that mushroom intake, together with other phytotherapy substances, protects against cancer, specifically gastrointestinal (GI) and breast cancers. Most of the data come from in vitro studies and in vivo experimental animal models. Therefore, in order to translate the updated knowledge to clinical research (i.e., from bench to bedside) a systematic translational research program should be initiated. Future randomized controlled trials comparing the effects of G. frondosa and G. lucidum on conventional treatment outcomes are warranted. The purpose of this review was to describe the emerging mechanisms of action of the mushrooms' anticancer functions which makes their use in clinical practice so promising. Clinical effects of mycotherapy (specifically, the use of Ganoderma lucidum and Grifola frondosa) on long-term survival, tumor response, host immune functions, inflammation, and QoL in cancer patients were also addressed. Adverse events associated with mycotherapy were also investigated. Emerging data point to a potential role of G. lucidum for modulating the carcinogenic potential of GI microbiota, which suggests a new complementary and integrated approach to breast cancer treatment.
U2 - 10.18632/oncotarget.24984
DO - 10.18632/oncotarget.24984
M3 - Review article
C2 - 29872510
VL - 9
SP - 24837
EP - 24856
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 37
ER -